Data from Fineline Cube indicates that JDB153, a potential first-in-class (FIC) small-molecule inhibitor targeting Mnk and VEGFR developed by China-based biotech Jumbo Drug Bank, entered a Phase I clinical study on June 13, 2022. The trial, initiated one week after receiving approval from the National Medical Products Administration (NMPA), is evaluating the safety, efficacy, and pharmacokinetics of JDB153 as a monotherapy in advanced solid tumors. Conducted at the West China Hospital of Sichuan University, the study is expected to enroll 35-50 patients.
Drug Mechanism and Development
Jumbo Drug Bank, a Chengdu-based early-stage biotech established in 2019, is developing JDB153, the world’s first MNK/VEGFR dual-targeted small-molecule drug. JDB153 works by down-regulating MYC to inhibit the phosphorylation level of eukaryotic initiation factor 4E, enhancing T cell activity, and synergizing with PD-1/L1 antibody therapies. It also inhibits vascular endothelial growth factor receptor, tumor cell differentiation, and new tumor angiogenesis.
Pre-Clinical Results
In pre-clinical studies, JDB153 demonstrated excellent safety, tolerability, and anticancer activities across multiple solid tumor models. These findings support its potential as a novel therapeutic option for advanced solid tumors.-Fineline Info & Tech
